Top

Published in:

01-02-2019 | Review

Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE)

Authors: Danielle A. Henry, Marie C. Lee, Deanna Almanza, Kamran A. Ahmed, Weihong Sun, David C. Boulware, Christine Laronga

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Abstract

Purpose

Awareness of inherited breast cancer has increased bilateral prophylactic mastectomy (BPM) among unaffected genetic mutation carriers, yet many still choose surveillance. We aimed to identify differences among women electing BPM vs high-risk surveillance.

Methods

Participants from an IRB-approved database recruited from 11/2000 to 01/2017 with a deleterious/pathogenic, variant suspected deleterious, or likely pathogenic mutation in ≥ 1 of 11 genes with increased risk for breast cancer (per 2017 NCCN guidelines) were identified. Participants with breast cancer and males were excluded. Sociodemographic and clinical data were collected. The BPM and high-risk surveillance groups were compared using Wilcoxon, Fisher’s Exact, and Pearson’s Chi-Square analyses.

Results

A total of 304 unaffected genetic mutation carriers were identified; 22 men were excluded. 113/282 (40%) underwent BPM. There was no significant difference in age, race, marital status, high school graduates, family history of breast cancer, breast biopsies, chemoprevention use, or understanding implications of genetic mutation carriage. BPM participants were more likely to have a prior pregnancy (p = 0.0005), college education (p = 0.04), income > $50,000/year (p = 0.01), first-degree relative with breast cancer (p = 0.04), higher total number of relatives with breast cancer (p = 0.01), and rate of risk-reducing salpingo-oophorectomy (p = < 0.0001). The high-risk surveillance group was more likely to have a history of ovarian cancer (p = 0.009) and cancer worry (p = < 0.0001).

Conclusions

BPM is a common but not universal choice among unaffected genetic carriers of inherited breast cancer syndromes. Parity, education, income, ovarian cancer history, first-degree relatives with breast cancer, and cancer worry play significant roles in these decisions.

PDQ Adult Treatment Editorial Board (2018) PDQ® Breast Cancer Treatment. http://www.ncbi.nlm.nih.gov/pubmed/26389406. Accessed 14 Apr 2018

American Cancer Society (2018) Cancer Facts & Figs. 2018. https://doi.org/10.3322/caac.21442

Powers B, Pal T, Laronga C (2018) Considerations in testing for inherited breast cancer predisposition in the era of personalized medicine. Surg Oncol Clin N Am 27:1–22. https://doi.org/10.1016/j.soc.2017.08.003 CrossRefPubMed

Genetic/Familial High-Risk Assessment (2018): Breast and Ovarian. In: NCCN Clin. Pract. Guidel. Oncol. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 3 Feb 2018

Ponder B (1997) Genetic testing for cancer risk. Science 278:1050–1054. https://doi.org/10.1126/SCIENCE.278.5340.1050 CrossRefPubMed

PDQ® Cancer Genetics Editorial Board PDQ Genetics of Breast and Gynecologic Cancers (2018): Health Professional Version. In: Bethesda, MD Natl. Cancer Institute. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq. Accessed 3 Feb 2018

American Cancer Society (2017) Breast Cancer Facts & Figs. 2017–2018

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689CrossRefPubMedPubMedCentral

American Society of Clinical Oncology (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736CrossRef

10.

Supreme Court of the United States (2013) Association for molecular pathology et al. v. Myriad Genetics, Inc. https://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf. Accessed 20 Apr 2018

11.

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van’t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 22:1055–1062. https://doi.org/10.1200/JCO.2004.04.188 CrossRefPubMed

12.

Padamsee TJ, Wills CE, Yee LD, Paskett ED (2017) Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res. https://doi.org/10.1186/s13058-017-0826-5 CrossRefPubMedPubMedCentral

13.

Domchek SM, Friebel TM, Singer CF, Evans DG, Henry T, Isaacs C, Garber JE, Neuhausen SL, Matloff E (2010) Europe PMC Funders Group Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975. https://doi.org/10.1001/jama.2010.1237 CrossRefPubMedPubMedCentral

14.

Heemskerk-Gerritsen BAM, Menke-Pluijmers MBE, Jager A, Tilanus-Linthorst MMA, Koppert LB, Obdeijn IMA, van Deurzen CHM, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24:2029–2035. https://doi.org/10.1093/annonc/mdt134 CrossRefPubMed

15.

Ne C, Lostumbo L, Wallace J, Ko H, Carbine NE, Lostumbo L, Wallace J, Ko H (2018) Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev doi. https://doi.org/10.1002/14651858.CD002748.pub4 CrossRef

16.

Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Grant CS, Michels VV, Jenkins RB (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84. https://doi.org/10.1056/NEJM199901143400201 CrossRefPubMed

17.

Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DGR (2013) Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat 142:611–618. https://doi.org/10.1007/s10549-013-2765-x CrossRefPubMed

18.

Euhus D (2014) Genetic testing today. Ann Surg Oncol 21:3209–3215. https://doi.org/10.1245/s10434-014-3906-0 CrossRefPubMed

19.

Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89. https://doi.org/10.3322/canjclin.57.2.75

20.

Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, Tombach B, Leutner C, Rieber-Brambs A, Nordhoff D, Heindel W, Reiser M, Schild HH (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28:1450–1457. https://doi.org/10.1200/JCO.2009.23.0839 CrossRefPubMed

21.

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664–1669. https://doi.org/10.1200/JCO.2009.27.0835 CrossRefPubMedPubMedCentral

22.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107:24–30. https://doi.org/10.1038/bjc.2012.204 CrossRefPubMedPubMedCentral

23.

Skytte A-B, Gerdes A-M, Andersen MK, Sunde L, Brøndum-Nielsen K, Waldstrøm M, Kølvraa S, Crüger D (2010) Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 77:342–349. https://doi.org/10.1111/j.1399-0004.2009.01329.x CrossRefPubMed

24.

Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M (2017) Differences Among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance. Ann Surg Oncol 24:3048–3054. https://doi.org/10.1245/s10434-017-5976-2 CrossRefPubMedPubMedCentral

25.

Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA (2012) Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 133:735–740. https://doi.org/10.1007/s10549-011-1941-0 CrossRefPubMed

26.

Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker J-P, Tennevet I, Chabbert-Buffet N, This P, Baudry K, Lemonnier J, Roca L, Mijonnet S, Gesta P, Chiesa J, Dreyfus H, Vennin P, Delnatte C, Bignon YJ, Lortholary A, Prieur F, Gladieff L, Lesur A, Clough KB, Nogues C, Martin A-L, French Federation of Cancer Centres (FNCLCC) (2012) Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer 11:77–84. https://doi.org/10.1007/s10689-011-9484-4 CrossRefPubMed

27.

Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L (2012) Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 118:510–517. https://doi.org/10.1002/cncr.26294 CrossRefPubMed

28.

Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, Bonney A, Lynch JF, Narod SA, Lynch HT (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (Baltim) 31:75–80. https://doi.org/10.1006/pmed.2000.0684 CrossRef

29.

Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review - full. Am J Surg 212:660–669. https://doi.org/10.1016/j.amjsurg.2016.06.010 CrossRefPubMed

30.

Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod SA (2008) Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 73:474–479. https://doi.org/10.1111/j.1399-0004.2008.00988.x CrossRefPubMed

31.

Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR (2007) Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7:875–882. https://doi.org/10.3816/CBC.2007.n.053 CrossRefPubMed

32.

McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA (2017) Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted? Gynecol Oncol 145:346–351. https://doi.org/10.1016/j.ygyno.2017.02.032 CrossRefPubMed

Title: Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE)
Authors: Danielle A. Henry
Marie C. Lee
Deanna Almanza
Kamran A. Ahmed
Weihong Sun
David C. Boulware
Christine Laronga
Publication date: 01-02-2019
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-5057-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy

Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials

Glutamate dehydrogenase (GLUD1) expression in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer